ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,37%
Bitcoin
61.288,10
0,80%
Brent Oil
82,585
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) Notícias

ALT

Altimmune (ALT)

Altimmune Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALT
DataHoraFonteTítuloCódigoCompanhia
10/05/202406:45PR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) ShareholdersNASDAQ:ALTAltimmune Inc
09/05/202418:51PR Newswire (US)INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law FirmNASDAQ:ALTAltimmune Inc
09/05/202417:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALTAltimmune Inc
09/05/202408:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALTAltimmune Inc
09/05/202408:00GlobeNewswire Inc.Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
07/05/202408:30GlobeNewswire Inc.Altimmune to Participate at Two Upcoming Investor ConferencesNASDAQ:ALTAltimmune Inc
02/05/202408:30GlobeNewswire Inc.Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024NASDAQ:ALTAltimmune Inc
01/05/202408:30GlobeNewswire Inc.Altimmune to Participate at Two Upcoming ConferencesNASDAQ:ALTAltimmune Inc
25/04/202418:24GlobeNewswire Inc.Altimmune Statement on the Passing of Dr. Stephen HarrisonNASDAQ:ALTAltimmune Inc
27/03/202408:00GlobeNewswire Inc.Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALTAltimmune Inc
27/03/202407:57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:ALTAltimmune Inc
20/03/202408:30GlobeNewswire Inc.Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024NASDAQ:ALTAltimmune Inc
14/02/202414:04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALTAltimmune Inc
05/02/202420:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALTAltimmune Inc
26/01/202413:49Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALTAltimmune Inc
02/01/202409:30GlobeNewswire Inc.Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024NASDAQ:ALTAltimmune Inc
08/12/202310:35GlobeNewswire Inc.Water Tower Research US Climate Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:ALTAltimmune Inc
04/12/202310:35GlobeNewswire Inc.Water Tower Research US Climate Investor Conference Agenda Announced for December 7th, 2023NASDAQ:ALTAltimmune Inc
30/11/202318:24GlobeNewswire Inc.Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of PemvidutideNASDAQ:ALTAltimmune Inc
07/11/202309:00GlobeNewswire Inc.Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
31/10/202308:30GlobeNewswire Inc.Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023NASDAQ:ALTAltimmune Inc
26/10/202309:15Dow Jones NewsAltimmune Gets FDA Fast-Track Designation for Pemvidutide in NASHNASDAQ:ALTAltimmune Inc
26/10/202308:30GlobeNewswire Inc.Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)NASDAQ:ALTAltimmune Inc
25/10/202308:30GlobeNewswire Inc.Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023NASDAQ:ALTAltimmune Inc
26/09/202308:30GlobeNewswire Inc.Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of DiabetesNASDAQ:ALTAltimmune Inc
12/09/202308:30GlobeNewswire Inc.Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or OverweightNASDAQ:ALTAltimmune Inc
16/08/202317:14Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ALTAltimmune Inc
16/08/202317:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALTAltimmune Inc
10/08/202308:00GlobeNewswire Inc.Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
03/08/202308:30GlobeNewswire Inc.Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023NASDAQ:ALTAltimmune Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BHIA3
Grupo Casas Bahia ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
IDIV
Dividend
BOV
TELB4
TELEBRAS PN
BOV
GUAR3
GUARARAPES ON
BOV
PETR4
PETROBRAS PN
BOV
LREN3
LOJAS RENNER ON
BOV
PETZ3
Pet Center Comercio E Pa... ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados